---
title: "GeoVax Labs (GOVX) news: reverse split and going concern"
url: "https://aibio.space/companies/geovax-labs/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "GOVX reverse split, going concern, offering and Nasdaq notice news: GeoVax stockholders approve reverse split of up to 1-for-25 and warrant share issuance."
---

GOVX GeoVax Labs, Inc. NASDAQ · United States

# GeoVax Labs (GOVX) news GOVX reverse split, going concern and offering news

Listings · 2026-10-27

## [GeoVax signs $1,000,000 credit line as five directors make way for lender nominees](https://aibio.space/news/geovax-signs-1-000-000-credit-line-five-directors-make-way-lender/)

GeoVax can borrow up to $1,000,000 at 12% interest from Bowery Consulting Group, and it agreed to pursue a public offering of at least $5,000,000. The lender designated the new directors.

## Latest GeoVax Labs news

1. 2026-10-27 Listings [GeoVax stockholders approve reverse split of up to 1-for-25 and warrant share issuance](https://aibio.space/news/geovax-stockholders-approve-reverse-split-up-1-25-warrant-share/) The board will pick a reverse split ratio between 1-for-10 and 1-for-25. Holders also approved up to 11,395,256 shares for warrants issued in August 2026, against 9,093,871 shares outstanding at the record date.
2. 2026-03-31 Distress [GeoVax Labs files NT 10-K, says 2025 annual report will be late](https://aibio.space/news/geovax-labs-files-nt-10-k-says-2025-annual-report-will-late/) GeoVax missed the March 31, 2026 deadline for its 2025 annual report and expects to file within 15 days. It expects a 2025 net loss of about $21.5 million, and its 2024 annual report carried a going-concern warning from the auditors.
3. 2026-02-17 Financings [GeoVax closes registered direct offering at $2.31 per share with net proceeds of about $865,000](https://aibio.space/news/geovax-closes-registered-direct-offering-2-31-share-net-proceeds-about/) GeoVax sold 402,000 shares and pre-funded warrants for up to 30,902 shares, plus Series A-1 and A-2 warrants in a concurrent private placement. H.C. Wainwright & Co., LLC was placement agent.
4. 2025-08-01 Listings [GeoVax receives Nasdaq bid price deficiency notice, has until January 27, 2026](https://aibio.space/news/geovax-receives-nasdaq-bid-price-deficiency-notice-has-until-january/) GeoVax's closing bid price was below $1.00 for 30 consecutive business days, according to a July 31, 2025 deficiency letter. The first deadline is January 27, 2026, and a second 180-day period is possible.
5. 2025-07-02 Financings [GeoVax Labs sells 9,235,000 units at $0.65 in public offering](https://aibio.space/news/geovax-labs-sells-9-235-000-units-0-65-public-offering/) Each unit carried one share and two warrants exercisable at $0.65. Estimated net proceeds are $5,582,557.50, and the lead program is a COVID-19 vaccine whose key comparison trial is still ahead.

## GeoVax Labs at a glance

- **Ticker**: GOVX

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $3.1 million

### Related companies

- [NeOnc Technologies Holdings](https://aibio.space/companies/neonc-technologies/) NASDAQ: NTHI
- [Neutra](https://aibio.space/companies/neutra/) OTC: NTRR
- [Prelude Therapeutics](https://aibio.space/companies/prelude-therapeutics/) NASDAQ: PRLD
- [UMeWorld](https://aibio.space/companies/umeworld/) OTC: UMEW
- [Mosaic ImmunoEngineering](https://aibio.space/companies/mosaic-immunoengineering/) OTC: CPMV
- [Zenas BioPharma](https://aibio.space/companies/zenas-biopharma/) NASDAQ: ZBIO
- [Entrada Therapeutics](https://aibio.space/companies/entrada-therapeutics/) NASDAQ: TRDA
- [Benitec Biopharma](https://aibio.space/companies/benitec-biopharma/) NASDAQ: BNTC

### Also on NASDAQ

- [First Tracks Biotherapeutics](https://aibio.space/companies/first-tracks-biotherapeutics/) TRAX
- [Biogen](https://aibio.space/companies/biogen/) BIIB
- [Amgen](https://aibio.space/companies/amgen/) AMGN
- [TScan Therapeutics](https://aibio.space/companies/tscan-therapeutics/) TCRX
- [BIOHARVEST SCIENCES INC.](https://aibio.space/companies/bioharvest-sciences/) BHST
- [Ligand Pharmaceuticals](https://aibio.space/companies/ligand-pharmaceuticals/) LGND

## What GeoVax Labs does

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers, using novel proprietary platforms. Its primary near-term strategic development priority is GEO-MVA, a Modified Vaccinia Ankara vaccine candidate for mpox, smallpox and other poxviruses, which is advancing on an expedited regulatory pathway in Europe. The company plans to initiate a pivotal Phase 3 trial in the second half of 2026 and says GEO-MVA is intended to address a significant global supply constraint for orthopoxvirus vaccines. Its lead clinical oncology program, Gedeptin, is an oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 trial for advanced head and neck cancers. A Phase 2 trial combining Gedeptin with an immune checkpoint inhibitor is planned to start in the first half of 2027. GeoVax is also developing GEO-CM04S1, a multi-antigen COVID-19 vaccine evaluated in Phase 2 trials, including as a primary vaccine for immunocompromised patients and as a booster in patients with chronic lymphocytic leukemia. The company holds NIH rights covering preclinical, clinical and commercial uses of NIH-MVA against mpox and smallpox.

| Product or program | What it is | Stage |
|---|---|---|
| GEO-MVA | Modified Vaccinia Ankara vaccine candidate for mpox and smallpox | Phase 3 initiation planned for H2 2026 |
| Gedeptin | Oncolytic solid tumor gene-directed therapy for head and neck cancers | Phase 1/2 completed |
| GEO-CM04S1 | Multi-antigen next-generation COVID-19 vaccine | Phase 2 |

Summarised from the company's [10-K filed Apr 15, 2026](https://www.sec.gov/Archives/edgar/data/832489/000143774926012377/govx20251231_10k.htm).

## GeoVax Labs annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$18.1 million](https://www.sec.gov/Archives/edgar/data/832489/000143774926012377/) | [$23.7 million](https://www.sec.gov/Archives/edgar/data/832489/000143774926012377/) |
| Net income (loss) | [-$21.5 million](https://www.sec.gov/Archives/edgar/data/832489/000143774926012377/) | [-$25.0 million](https://www.sec.gov/Archives/edgar/data/832489/000143774926012377/) |
| Cash from operations | [-$21.5 million](https://www.sec.gov/Archives/edgar/data/832489/000143774926012377/) | [-$24.7 million](https://www.sec.gov/Archives/edgar/data/832489/000143774926012377/) |
| Cash and equivalents | [$3.1 million](https://www.sec.gov/Archives/edgar/data/832489/000143774926024523/) | [$5.5 million](https://www.sec.gov/Archives/edgar/data/832489/000143774926012377/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.1 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about GeoVax Labs

Did GeoVax Labs do a reverse stock split?

Our latest story on this, dated Oct 27, 2026: "GeoVax stockholders approve reverse split of up to 1-for-25 and warrant share issuance". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/geovax-stockholders-approve-reverse-split-up-1-25-warrant-share/).

Has GeoVax Labs issued a going-concern warning?

Our latest story on this, dated Mar 31, 2026: "GeoVax Labs files NT 10-K, says 2025 annual report will be late". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/geovax-labs-files-nt-10-k-says-2025-annual-report-will-late/).

Has GeoVax Labs raised money recently?

Our latest story on this, dated Oct 27, 2026: "GeoVax signs $1,000,000 credit line as five directors make way for lender nominees". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/geovax-signs-1-000-000-credit-line-five-directors-make-way-lender/).

Has GeoVax Labs received a Nasdaq deficiency notice?

Our latest story on this, dated Aug 1, 2025: "GeoVax receives Nasdaq bid price deficiency notice, has until January 27, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/geovax-receives-nasdaq-bid-price-deficiency-notice-has-until-january/).

What is the ticker symbol of GeoVax Labs?

GeoVax Labs, Inc. trades under the ticker GOVX on NASDAQ.

Where is GeoVax Labs listed?

GeoVax Labs, Inc. is listed on NASDAQ.

What is the SEC CIK of GeoVax Labs?

The SEC Central Index Key (CIK) for GeoVax Labs, Inc. is 832489. Its filings are on SEC EDGAR.

How many shares does GeoVax Labs have outstanding?

7,369,243 shares as of 2026-07-27, per the cover page of its 10-Q filed 2026-07-27.

Which country or territory is GeoVax Labs listed under?

Our directory records GeoVax Labs, Inc. under United States.

What does GeoVax Labs do?

Our directory classifies GeoVax Labs, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of GeoVax Labs?

The ISIN recorded for GeoVax Labs, Inc. is US3736787058.

Does aibio.space cover GeoVax Labs?

aibio.space lists GeoVax Labs, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is GeoVax Labs incorporated?

SEC records list its state or country of incorporation as DE.

What does GeoVax Labs develop?

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers, using novel proprietary platforms. Its primary near-term strategic development priority is GEO-MVA, a Modified Vaccinia Ankara vaccine candidate for mpox, smallpox and other poxviruses, which is advancing on an expedited regulatory pathway in Europe.

What is GEO-MVA from GeoVax Labs?

GEO-MVA: Modified Vaccinia Ankara vaccine candidate for mpox and smallpox Stage: Phase 3 initiation planned for H2 2026.

## Investor discussion: GeoVax Labs

Members talk about GeoVax Labs (GOVX). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at GeoVax Labs, newest first. Each line links the filing it comes from.

1. 2026-10-27 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,2.03,3.03,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774926033566/govx20261026_8k.htm)
2. 2026-10-27 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774926033610/govx20261027_8k.htm)
3. 2026-09-10 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774926030089/govx20260904_def14a.htm)
4. 2026-08-31 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774926029328/govx20260831_pre14a.htm)
5. 2026-08-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774926029184/govx20260828_8k.htm)
6. 2026-07-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774926023320/govx20260709_8k.htm)
7. 2026-04-15 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774926012377/govx20251231_10k.htm)
8. 2026-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774926010722/govx20260330_nt10k.htm)
9. 2026-01-26 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774926002009/govx20260125_424b5.htm)
10. 2026-01-12 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774926001113/govx20260109_8k.htm)
11. 2025-12-12 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774925037757/govx20251210c_s1.htm)
12. 2025-11-26 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774925036447/govx20251126_8k.htm)
13. 2025-10-14 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774925030934/govx20251010_def14a.htm)
14. 2025-10-03 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774925030491/govx20251002_pre14a.htm)
15. 2025-09-19 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774925029482/govx20250918_424b5.htm)
16. 2025-08-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774925024389/govx20250731_8k.htm)
17. 2025-07-02 Financings Reported a financing. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774925021857/govx20250701_424b4.htm)
18. 2025-06-16 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774925020507/govx20250612_s1.htm)
19. 2025-04-14 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774925011926/govx20250414_8k.htm)
20. 2025-03-27 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774925009614/govx20241231_10k.htm)
21. 2024-11-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/832489/000143774924035609/govx20241118_8k.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:GOVX on TradingView](https://www.tradingview.com/symbols/NASDAQ-GOVX/).

## SEC filings and registration

- **SEC name**: GeoVax Labs, Inc.

- **CIK**: 832489

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: GOVX (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 1955 LAKE PARK DRIVE, SMYRNA, GA

- **Phone**: 678-384-7220

- **Shares outstanding**: 7,369,243 as of 2026-07-27 (10-Q filed 2026-07-27)

- **Former names**: DAUPHIN TECHNOLOGY INC

### Recent filings (8-K and 6-K are the company's own announcements)

- [S-1](https://www.sec.gov/Archives/edgar/data/832489/000143774926030676/govx20260911c_s1.htm) filed 2026-09-17
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/832489/000143774926030089/govx20260904_def14a.htm) filed 2026-09-10
- [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774926030085/govx20260909_8k.htm) filed 2026-09-10
- [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774926029184/govx20260828_8k.htm) filed 2026-08-28
- [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774926029181/govx20260827_8k.htm) filed 2026-08-28
- [10-Q](https://www.sec.gov/Archives/edgar/data/832489/000143774926024523/govx20260630_10q.htm) filed 2026-07-27
- [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774926024522/govx20260727_8k.htm) filed 2026-07-27
- [8-K](https://www.sec.gov/Archives/edgar/data/832489/000143774926023320/govx20260709_8k.htm) filed 2026-07-10

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000832489), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

GeoVax Labs, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GOVX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: GeoVax Labs, Inc.

- **Ticker**: GOVX

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US3736787058

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-GOVX/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/geovax-labs/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "GeoVax Labs (GOVX) news: reverse split and going concern", 2026-10-31, https://aibio.space/companies/geovax-labs/